Health Care

Tenax Therapeutics insider buying signals confidence as the company’s new pulmonary hypertension therapy edges toward FDA Fast Track status, hinting at future upside.

Insider option purchases show cautious optimism for a fertility‑device firm. Despite a steep drop to $0.80, executives are buying stock options, hinting at confidence in upcoming R&D milestones and a potential rebound for investors.

Clene insider sale and warrant purchase shows confidence in FDA milestone‑driven ALS therapy, balancing liquidity with long‑term upside potential.

Explore the latest FDA‑approved oncology drugs—Tegafur‑S‑1, CAR‑T, Pembrolizumab + chemo, and TDM‑1—showing survival gains, safety, and precision‑medicine insights.

Elanco insider buying signals growing confidence in its pet‑health growth strategy and drug pipeline, offering investors a subtle yet optimistic cue for future value.

Enliven Therapeutics’ latest 10b5‑1 sale shows routine COO trading, while Phase II data for its pancreatic cancer drug and orphan‑drug status drive investor excitement and a near‑50% weekly rise in shares.

Insider sale of 4,896 Globus Medical shares by CFO Kyle Kline shows routine liquidity moves; strong executive buying, solid market position, and low‑risk growth keep investor confidence high.

Royalty Pharma insider Urist Marshall sells 20,000 shares near $40.78, reflecting a structured plan‑based move amid a Teva partnership that could boost royalties and stock upside.

Opus Genetics insider sale: 3,950 shares sold for tax reasons, yet senior exec buying shows confidence—analyzing liquidity and future funding risks.

Executive insider buying at Zymeworks signals confidence in its biotherapeutics pipeline—see how leadership moves, tax‑management, and future milestones could drive value.